Myozyme

Phase 2/3Completed

1 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glycogen Storage Disease Type II

Conditions

Glycogen Storage Disease Type II

Trial Timeline

Apr 1, 2003 → Sep 1, 2005

NCT ID

NCT00059280

About Myozyme

Myozyme is a phase 2/3 stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is completed. This product is registered under clinical trial identifier NCT00059280. Target conditions include Glycogen Storage Disease Type II.

What happened to similar drugs?

3 of 7 similar drugs in Glycogen Storage Disease Type II were approved

Approved (3) Terminated (0) Active (4)

✅ALGLUCOSIDASE ALFA (MYOZYME)SanofiApproved

✅Avalglucosidase alfa (GZ402666)SanofiApproved

✅Avalglucosidase alfaSanofiApproved

🔄avalglucosidase alfaSanofiPhase 3

🔄Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3

🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3

🔄Oral prednisolone + Placebo for oral prednisoloneUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00268944	Phase 3	Completed	Dec 1, 2005	Jun 1, 2007	Pompe Disease (Late-onset)
NCT00125879	Phase 2/3	Completed	Jun 1, 2005	Dec 1, 2006	Glycogen Storage Disease Type II
NCT00250939	Phase 2	Completed	Feb 1, 2005	Nov 1, 2006	Pompe Disease (Late-onset)
NCT00074932	Pre-clinical	Completed	Nov 1, 2004	Dec 1, 2006	Glycogen Storage Disease Type II
NCT00059280	Phase 2/3	Completed	Apr 1, 2003	Sep 1, 2005	Glycogen Storage Disease Type II
NCT00765414	Phase 2	Completed	Apr 1, 2003	Aug 1, 2006	Pompe Disease Late-Onset
NCT00763932	Phase 2	Completed	Apr 1, 2003	Jul 1, 2006	Pompe Disease Infantile-Onset
NCT00053573	Phase 1/2	Completed	Feb 1, 2003	Nov 1, 2006	Glycogen Storage Disease Type II

Competing Products

20 competing products in Glycogen Storage Disease Type II

See all competitors

Product	Company	Stage	Hype Score
mRNA-3745	Moderna	Phase 2	0
alglucosidase alfa	Sanofi	Pre-clinical	26
avalglucosidase alfa	Sanofi	Phase 3	44
Myozyme	Sanofi	Pre-clinical	26
Avalglucosidase Alfa	Sanofi	Phase 2	35
Myozyme	Sanofi	Phase 2/3	38
ALGLUCOSIDASE ALFA (MYOZYME)	Sanofi	Approved	43
Avalglucosidase alfa (GZ402666)	Sanofi	Approved	47
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 3	40
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)	Sanofi	Phase 2	39
Alglucosidase alfa	Sanofi	Phase 2	35
Avalglucosidase alfa	Sanofi	Approved	50
Myozyme	Sanofi	Phase 1/2	32
Alglucosidase alfa GZ419829	Sanofi	Pre-clinical	30
alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])	Sanofi	Pre-clinical	26
alglucosidase alfa	Sanofi	Pre-clinical	26
Cipaglucosidase alfa + Miglustat	Amicus Therapeutics	Phase 3	44
BEAM-301: Single dose of BEAM-301 administered by IV	Beam Therapeutics	Phase 1/2	33
Oral prednisolone + Placebo for oral prednisolone	Ultragenyx Pharmaceutical	Phase 3	34
UX053 + Antipyretic + H2 Blocker + H1 Blocker	Ultragenyx Pharmaceutical	Phase 1/2	18